Moleculin Historical Cash Flow

MBRX
 Stock
  

USD 1.70  0.01  0.58%   

Analysis of Moleculin Biotech cash flow over time is an excellent tool to project Moleculin Biotech future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Net Cash Flow from Financing of 80.6 M or Net Cash Flow Investment Acquisitions and Disposals of 207.8 K as it is a great indicator of Moleculin Biotech ability to facilitate future growth, repay debt on time or pay out dividends.Financial Statement Analysis is way more than just reviewing and evaluating Moleculin Biotech prevailing accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Moleculin Biotech is a good buy for the upcoming year.
Additionally, see Stocks Correlation.
  

About Moleculin Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Moleculin balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Moleculin's non-liquid assets can be easily converted into cash.

Moleculin Biotech Cash Flow Chart

Moleculin Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Moleculin Biotech Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
Moleculin Biotech Net Cash Flow or Change in Cash and Cash Equivalents is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Net Cash Flow or Change in Cash and Cash Equivalents of 55.73 Million in 2021. Issuance Purchase of Equity Shares is likely to rise to about 80.6 M in 2022, whereas Capital Expenditure is likely to drop (20.5 K) in 2022.

Issuance Purchase of Equity Shares

A component of Net Cash Flow from Financing representing the net cash inflow (outflow) from common equity changes. Includes additional capital contributions from share issuances and exercise of stock options; and outflow from share repurchases.

Net Cash Flow from Financing

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from financing activities; from continuing and discontinued operations. Principal components of financing cash flow are: issuance (purchase) of equity shares; issuance (repayment) of debt securities; and payment of dividends & other cash distributions.

Net Cash Flow from Investing

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from investing activities; from continuing and discontinued operations. Principal components of investing cash flow are: capital (expenditure) disposal of equipment Capital Expenditure; business (acquisitions) disposition Net Cash Flow Business Acquisitions and Disposals and investment (acquisition) disposal Net Cash Flow Investment Acquisitions and Disposals.

Net Cash Flow from Operations

A component of Net Cash Flow or Change in Cash and Cash Equivalents representing the amount of cash inflow (outflow) from operating activities; from continuing and discontinued operations.
Most accounts from Moleculin Biotech cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Moleculin Biotech current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Additionally, see Stocks Correlation.Moleculin Biotech Net Cash Flow or Change in Cash and Cash Equivalents is fairly stable at the moment as compared to the past year. Moleculin Biotech reported Net Cash Flow or Change in Cash and Cash Equivalents of 55.73 Million in 2021. Issuance Purchase of Equity Shares is likely to rise to about 80.6 M in 2022, whereas Capital Expenditure is likely to drop (20.5 K) in 2022.

Moleculin Biotech cash flow statement Correlations

Moleculin Biotech Account Relationship Matchups

Moleculin Biotech cash flow statement Accounts

201720182019202020212022 (projected)
Capital Expenditure(28 K)(417 K)(51 K)(374 K)(19 K)(20.5 K)
Depreciation Amortization and Accretion18 K68 K199 K200 K164 K135.33 K
Net Cash Flow or Change in Cash and Cash Equivalents2.71 M(580 K)3.6 M4.44 M55.73 M60.13 M
Issuance Purchase of Equity Shares10.06 M12.04 M20.85 M22.57 M74.75 M80.65 M
Net Cash Flow from Financing10.06 M12.04 M20.85 M22.55 M74.72 M80.62 M
Net Cash Flow from Investing(28 K)(417 K)(51 K)(374 K)(19 K)(20.5 K)
Net Cash Flow from Operations(7.32 M)(12.2 M)(17.2 M)(17.77 M)(18.95 M)(19.45 M)
Share Based Compensation707 K1.14 M1.54 M1.68 M2.37 M2 M

Be your own money manager

Our tools can tell you how much better you can do entering a position in Moleculin Biotech without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Analyzer Now

   

Idea Analyzer

Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moleculin Biotech using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see Stocks Correlation. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
48.6 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.